Skip to main content

Advertisement

Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

Fig. 4

Chronic treatment with SAR255952 prevents synaptic activity deficits in APPSL mice. A subgroup of the transgenic animals was maintained under treatment up to the age of 9–10 months for ex-vivo hippocampal brain slice electrophysiology. a Mean (± SEM) size of the extracellular field excitatory postsynaptic potentials (EPSP) recorded in the CA1 stratum radiatum in response to electrical stimuli of the indicated intensity applied to the Schaeffer collaterals of wild-type controls (brown circles), Ctrl-IgG1-treated controls (blue squares), or animals treated with 10 mg/kg i.p. SAR255992 (green diamonds). b Mean (± SEM) amplitude of the EPSP at the intermediate stimulation intensity of 250 μA (dotted line on a). #p < 0.05, versus wild-type controls; *p < 0.05, versus Ctrl-IgG1-treated controls

Back to article page